SCHEMBL32688076

SCHEMBL32688076

N#Cc1c(-c2cccc(-c3ccccc3)c2)cc(=O)[nH]c1S

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 8/20 0.50
▸ RECQL P46063 2/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ ATM Q13315 1/20 0.49
▸ PIM1 P11309 3/20 0.43
▸ BIRC5 O15392 2/20 0.43
▸ ALDH1A1 P00352 6/20 0.41
▸ HPGD P15428 6/20 0.41
▸ GAA P10253 3/20 0.41
▸ ACMSD Q8TDX5 1/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ GLA P06280 2/20 0.39
▸ RXFP1 Q9HBX9 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ BLM P54132 1/20 0.39
▸ PDE9A O76083 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ GALR3 O60755 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20339404 0.91 ATM (0.58) KDM4ERECQLTDP1ATMPIM1
SCHEMBL20340038 0.84 KDM4E (0.56) KDM4ERECQLTDP1ATMPIM1
SCHEMBL32688042 0.83 ACMSD (0.52) KDM4ERECQLTDP1ATMACMSD
SCHEMBL32688129 0.82 KDM4E (0.42) KDM4ERECQLTDP1ATMPIM1
SCHEMBL32688273 0.80 KDM4E (0.44) KDM4ERECQLTDP1ATMPIM1
SCHEMBL32687996 0.79 KDM4E (0.43) KDM4ERECQLTDP1ATMPIM1
SCHEMBL32688430 0.78 PDE9A (0.50) KDM4ERECQLATMPIM1BIRC5
SCHEMBL32688309 0.78 KDM4E (0.43) KDM4ERECQLTDP1ATMALDH1A1
SCHEMBL20340145 0.78 KDM4E (0.59) KDM4ERECQLTDP1ATMPIM1
SCHEMBL20339604 0.78 KDM4E (0.51) KDM4ERECQLTDP1ATMPIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078105-A1 Novel Aminocarboxymuconate Semialdehyde Decarboxylase Inhibitors ORSOBIO INC (US) 2026-03-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260078105-A1 Novel Aminocarboxymuconate Semialdehyde Decarboxylase Inhibitors CPT1B, CBR1, MUSK KDM4E 3207/4885RECQL 1365/4885TDP1 1571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback